Total Voting Rights

e-Therapeutics plc

28 April 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

Total Voting Rights    

London, UK, 28 April 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company has 582,659,332 ordinary shares of 0.1 pence each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 582,659,332.

The above figure of 582,659,332 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company.

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO Laura Roca-Alonso, COO	Tel: [phone] www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

About e-therapeutics plc www.etherapeutics.co.uk

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines.  The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.  

ETX's proprietary HepNetÔ platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource.  The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence. 

GalOmicÔ, ETX's proprietary RNAi platform, enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNetÔ.  The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases.  The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmicÔ constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action. 

The Company is progressing a pipeline of first-in-class pre-clinical RNAi candidates across a several high unmet medical needs in cardiometabolic indications and targeting promising hepatocyte-expressed with effects in other disease areas. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF. 

 

END